Neoplasms

United States Basal Cell Carcinoma Market and Competitive Landscape Report 2021 - ResearchAndMarkets.com

Retrieved on: 
Friday, February 12, 2021
Pharmaceutical, Health, Oncology, Carcinoma, Basal-cell carcinoma, Histopathology, Neoplasms, Clinical medicine, Medical specialties

The "US Basal Cell Carcinoma Market and Competitive Landscape - 2021" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "US Basal Cell Carcinoma Market and Competitive Landscape - 2021" report has been added to ResearchAndMarkets.com's offering.
  • US Basal Cell Carcinoma Market and Competitive Landscape Highlights - 2021, provides comprehensive insights into Basal Cell Carcinoma pipeline products, Basal Cell Carcinoma epidemiology, Basal Cell Carcinoma market valuations and forecast, Basal Cell Carcinoma drugs sales and competitive landscape in the US.
  • Basal Cell Carcinoma pipeline: Find out the products in clinical trials for the treatment of Basal Cell Carcinoma by development phase 3, phase 2, and phase 1, by pharmacological class and companies developing the products
    Basal Cell Carcinoma drugs: Identify key products marketed and prescribed for Basal Cell Carcinoma in the US, including trade name, molecule name, and company
    Basal Cell Carcinoma drugs sales: Find out the sales revenues of Basal Cell Carcinoma drugs in the US
    Basal Cell Carcinoma market valuations: Find out the market size for Basal Cell Carcinoma drugs in 2019 in the US.
  • Find out how the market advanced from 2017 and forecast to 2026
    Basal Cell Carcinoma drugs market share: Find out the market shares for key Basal Cell Carcinoma drugs in the US
    Evaluate commercial market opportunity assessment, positioning, and segmentation for Basal Cell Carcinoma products
    View source version on businesswire.com: https://www.businesswire.com/news/home/20210212005351/en/

Profound Medical to Release Fourth Quarter and Full Year 2020 Financial Results on March 2 – Conference Call to Follow

Retrieved on: 
Tuesday, February 9, 2021
Neoplasms, Sonalleve MR-HIFU, Uterine fibroid, Bone metastasis, Clinical medicine, Medicine, Medical ultrasonography, Surgical oncology

Profound is a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue.

Key Points: 
  • Profound is a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue.
  • Profound is commercializing TULSA-PRO, a technology that combines real-time MRI, robotically-driven transurethral ultrasound and closed-loop temperature feedback control.
  • TULSA-PRO is CE marked, Health Canada approved, and 510(k) cleared by the U.S. Food and Drug Administration (FDA).
  • Profound is also commercializing Sonalleve, an innovative therapeutic platform that is CE marked for the treatment of uterine fibroids and palliative pain treatment of bone metastases.

New Study from Foundation Medicine and Collaborators Further Demonstrates the Clinical Utility of Blood-Based Comprehensive Genomic Profiling in Patients with Advanced Prostate Cancer

Retrieved on: 
Tuesday, February 9, 2021
Oncology, Health, Genetics, Clinical trials, Pharmaceutical, Biotechnology, Clinical medicine, Medicine, Medical specialties, Oncology, DNA, Anatomical pathology, Circulating tumor DNA, Neoplasms, Liquid biopsy, Biopsy, Prostate cancer, MCRPC

The study demonstrated high concordance between targetable alterations identified using circulating tumor DNA (ctDNA) and tissue-based comprehensive genomic profiling (CGP) in patients with metastatic castration-resistant prostate cancer (mCRPC).

Key Points: 
  • The study demonstrated high concordance between targetable alterations identified using circulating tumor DNA (ctDNA) and tissue-based comprehensive genomic profiling (CGP) in patients with metastatic castration-resistant prostate cancer (mCRPC).
  • It also found that, in many patients, liquid biopsy detects more acquired resistance mechanisms than tissue biopsy.
  • The study, Genomic analysis of circulating tumor DNA (ctDNA) in 3,334 patients with advanced prostate cancer identifies targetable BRCA alterations and AR resistance mechanisms, was published online in Clinical Cancer Research , a journal of the American Association for Cancer Research.
  • Foundation Medicine is a registered trademark of Foundation Medicine, Inc.
    1 American Cancer Society Key Statistics for Prostate Cancer: https://www.cancer.org/cancer/prostate-cancer/about/key-statistics.html
    2 Cancer.Net .

Cue Biopharma Initiates Patient Dosing in Phase 1 Study of CUE-101 in Combination with KEYTRUDA® (pembrolizumab) as First-line Treatment for HPV+ Recurrent/Metastatic Head and Neck Cancer

Retrieved on: 
Monday, February 8, 2021
Cancer, Neoplasms, Clinical medicine, RTT, Antineoplastic drugs, Breakthrough therapy, Head and neck cancer, Otorhinolaryngology, Pembrolizumab, Head and neck squamous-cell carcinoma, Human papillomavirus infection, Papilloma

CUE-101 is being evaluated in combination with KEYTRUDA as first-line treatment for human papilloma virus positive recurrent/metastatic head and neck squamous cell carcinoma (HPV+ R/M HNSCC).

Key Points: 
  • CUE-101 is being evaluated in combination with KEYTRUDA as first-line treatment for human papilloma virus positive recurrent/metastatic head and neck squamous cell carcinoma (HPV+ R/M HNSCC).
  • We are very pleased to have initiated our combination trial of CUE-101 with KEYTRUDA, said Ken Pienta, M.D, acting chief medical officer of Cue Biopharma.
  • These data taken together support our belief that the combination of CUE-101 with KEYTRUDA has the potential to enhance anti-tumor activity and prolong patient survival.
  • This Phase 1 dose escalation combination trial ( NCT03978689 ) is being conducted in parallel at the same clinics that are conducting the ongoing Phase 1 monotherapy study of CUE-101.

Spectrum Solutions Collaborates with UCLA on Saliva-Based Next-Gen Sequencing (NGS) Liquid Biopsy Research for the Early Detection of Lung Cancer

Retrieved on: 
Wednesday, January 27, 2021
Research, Medical devices, Genetics, Biotechnology, Health, University, Science, Education, Oncology, Medicine, Clinical medicine, Medical specialties, DNA, Oncology, Anatomical pathology, Circulating tumor DNA, Neoplasms, Biopsy, Cancer, CAPP-Seq

Spectrum Solutions, LLC today announced its sponsored research collaboration with the UCLA School of Dentistry for a study on using saliva in early lung cancer detection and analysis.

Key Points: 
  • Spectrum Solutions, LLC today announced its sponsored research collaboration with the UCLA School of Dentistry for a study on using saliva in early lung cancer detection and analysis.
  • Spectrum has funded a study that aims to recruit 50 patients with lung cancer and seeks to validate salivas tumor-specific ctDNA detection sensitivity and positive agreement against tissue biopsy-based genotyping.
  • Saliva will be collected, preserved, and transported for DNA testing using Spectrums Saliva Collection System.
  • Spectrum Solutions is a single-source provider of on-site medical device development and manufacturing, custom packaging, kitting, and direct-to-consumer fulfillment.

Gynesonics Announces That Detroit Medical Center Huron Valley-Sinai Hospital has Introduced Sonata, A New Innovative, Incision-Free Treatment for Symptomatic Uterine Fibroids

Retrieved on: 
Thursday, January 21, 2021
Health, Medical devices, Consumer, Women, Surgery, Other Health, General Health, Detroit Medical Center, Tenet Healthcare, Neoplasms, Benign neoplasms, Medicine, Gynaecological neoplasia, Uterine fibroid, Clinical medicine, Sinai-Grace Hospital, Huron Valley-Sinai Hospital, Transcervical, Uterine artery embolization, Sonata System, Gynesonics

Gynesonics, a womens healthcare company focused on the development of minimally invasive solutions for symptomatic uterine fibroids, announced today that Detroit Medical Center (DMC) Huron Valley-Sinai Hospital is the first hospital in Michigan to introduce the Sonata Procedure.

Key Points: 
  • Gynesonics, a womens healthcare company focused on the development of minimally invasive solutions for symptomatic uterine fibroids, announced today that Detroit Medical Center (DMC) Huron Valley-Sinai Hospital is the first hospital in Michigan to introduce the Sonata Procedure.
  • Symptoms may worsen over time if fibroids are left untreated, which leads to more than two million women in the U.S. undergoing treatment for uterine fibroids each year.
  • I was very impressed by the results of the clinical studies, and the positive impact Sonata had on womens lives.
  • Gynesonics has developed the Sonata System for diagnostic intrauterine imaging and transcervical treatment of symptomatic uterine fibroids.

Advaxis Announces Receipt of Funding Milestone Payment Under ADXS-HER2 Licensing Agreement with OS Therapies

Retrieved on: 
Tuesday, January 19, 2021
Cancer in cats, Cancer in dogs, Osteosarcoma, Sarcoma, Cancer, Neoplasms, Health

OS Therapies secured funding to support this research, triggering the first milestone payment.

Key Points: 
  • OS Therapies secured funding to support this research, triggering the first milestone payment.
  • Under the agreement, Advaxis will receive additional clinical, regulatory, and sales-based milestone payments as well as royalties on future product sales.
  • We are pleased that OS Therapies is now in position to initiate human clinical trials of OST-HER2 in osteosarcoma, said Kenneth A. Berlin, President and Chief Executive Officer of Advaxis.
  • Paul Romness, Chief Executive Officer of OS Therapies, said, The OS Therapies mission is to develop and commercialize new therapeutics for the treatment of osteosarcoma, a deadly and extremely underserved pediatric cancer.

Salarius Pharmaceuticals Announces Dr. Daniela Santiesteban to Participate in Panel Discussion on Targeted Cancer Therapies During Virtual NobleCon17 Investor Conference

Retrieved on: 
Friday, January 15, 2021
Anatomical pathology, Sarcoma, Ewing's sarcoma, Oncology, Neoplasms, Branches of biology, Cancer

Salarius also expects to expand the same trial to include additional select sarcomas that share a similar biology to Ewing sarcoma, also known as Ewing-related sarcomas.

Key Points: 
  • Salarius also expects to expand the same trial to include additional select sarcomas that share a similar biology to Ewing sarcoma, also known as Ewing-related sarcomas.
  • Salarius Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing cancer therapies for patients that need them the most.
  • Salarius lead candidate, seclidemstat, is being studied as a potential treatment for pediatric cancers, solid tumors and other cancers with limited treatment options.
  • Salarius may not actually achieve the plans, carry out the intentions or meet the expectations or objectives disclosed in the forward-looking statements.

Osteosarcoma Epidemiology Report 2020: In-depth Understanding, Historical and Forecasted Epidemiology Data 2017-2030

Retrieved on: 
Tuesday, January 12, 2021
Pediatric cancers, Sarcoma, Cancer in cats, Cancer in dogs, Osteosarcoma, Anatomical pathology, Cancer, Neoplasms, Medical specialties

This 'Osteosarcoma - Epidemiology Forecast-2030' report delivers an in-depth understanding of the Osteosarcoma, historical and forecasted epidemiology as well as the Osteosarcoma trends in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom) and Japan.

Key Points: 
  • This 'Osteosarcoma - Epidemiology Forecast-2030' report delivers an in-depth understanding of the Osteosarcoma, historical and forecasted epidemiology as well as the Osteosarcoma trends in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom) and Japan.
  • The disease epidemiology covered in the report provides historical as well as forecasted epidemiology segmented by Total Incident Cases of Osteosarcoma, Gender-specific Incident Cases of Osteosarcoma, Age-specific Incident Cases of Osteosarcoma, Stage-specific Incident Cases of Osteosarcoma, Sub-types specific Incident Cases of Osteosarcoma, and Site-specific Incident Cases of Osteosarcoma scenario of Osteosarcoma in the 7MM covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom) and Japan from 2017 to 2030.
  • As per the publisher's estimates, the Incident cases of Osteosarcoma in the 7MM were 2,181 cases in 2017 during the study period (2017-2030).
  • In the US, Conventional osteosarcoma accounted for nearly 80% of total osteosarcoma cases.

Osteosarcoma Epidemiology Forecast to 2030 - ResearchAndMarkets.com

Retrieved on: 
Monday, January 11, 2021
Health, Oncology, Pediatric cancers, Sarcoma, Cancer in cats, Cancer in dogs, Osteosarcoma, Anatomical pathology, Cancer, Neoplasms, Medical specialties

The "Osteosarcoma - Epidemiology Forecast to 2030" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Osteosarcoma - Epidemiology Forecast to 2030" report has been added to ResearchAndMarkets.com's offering.
  • This 'Osteosarcoma - Epidemiology Forecast-2030' report delivers an in-depth understanding of the Osteosarcoma, historical and forecasted epidemiology as well as the Osteosarcoma trends in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom) and Japan.
  • The disease epidemiology covered in the report provides historical as well as forecasted epidemiology segmented by Total Incident Cases of Osteosarcoma, Gender-specific Incident Cases of Osteosarcoma, Age-specific Incident Cases of Osteosarcoma, Stage-specific Incident Cases of Osteosarcoma, Sub-types specific Incident Cases of Osteosarcoma, and Site-specific Incident Cases of Osteosarcoma scenario of Osteosarcoma in the 7MM covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom) and Japan from 2017 to 2030.
  • In the US, Conventional osteosarcoma accounted for nearly 80% of total osteosarcoma cases.